Issels Integrative Immuno-Oncology June 25, 2015  

Expensive Biologic Drugs May Face Competition from the FDA and Biosimilars

Dear Friend,

Biologic drugs are often used to effectively treat serious, life threatening diseases. The downside, however, is cost – on average 20 times more than traditional chemical drugs – hundreds of thousands of dollars per year, per patient, annually. It's not surprising that these costs are neither sustainable for the average household – or the government. At Issels® we know access to affordable medication, such as biologics, can be essential to your cancer treatment success, so we wanted to let you know about the latest efforts in making these medicines more reasonable for consumers.

Step in biosimilars...

Expensive to produce, biosimilars are to biologics what generics are to name brand chemical drugs. The hope is by allowing competition in the market through the production of biosimilars, a more affordable option will be available to consumers than current high-cost biologics.

What's the holdup?

The 2010 Patient Protection and Affordable Care Act (PPACA) granted the FDA authority to develop a mechanism for approval of biosimilars, but guidelines have yet to be finalized. Interestingly, the FDA accepted its first application last week despite this fact. Many would-be manufacturers are dragging their feet, however, unwilling to take an investment risk without definitive guidelines and knowledge delays caused by biologics – the inventors of these medications – will halt development and approval.

How much will it save?

Similar programs in the E.U., who unlike the U.S. also regulates prices, have resulted in an average savings of about 30 percent less than branded biologics, keeping tens of billions in the pockets of the government and consumers.

Looking for an effective alternative to your expensive cancer treatment medications?  Contact Issels® today.


Read more interesting articles on the "Issels Integrative Immuno-Oncology" news/blog posted every Monday, Wednesday, and Friday. Check It Out Now »

Vitamin D Plays a Role in Pancreatic Cancer Unlocking New Potential Treatments

A study by the Salk Institute has found that a derivative from vitamin D weakens and collapses the shield protecting tumors. The findings from the study have resulted in both human and animal clinical trials. The outlook for vitamin D as a positive influence on weakening protective cells surrounding tumors may also mean other difficult tumors, such as those found in the liver, kidney, and lungs, will also be susceptible to treatment.

Get the Full Story!

Nanoparticles: Attacking Cancer from All Angles

The second leading cause of death in the U.S., the fight against cancer needs all the weapons in its arsenal that it can get. Step-in nanoparticles, tiny but tough tools ready for battle in the war. Find out how this new technology may bring a treatment break through.

Get the Full Story!

Videos – What Do Patients Say About Their Experience?

Watch videos of patients who share their own experiences at the Issels clinics with you. Listen to their stories and cancer journeys.

Get the Full Story!

Learn More

Testimonials »

Treatments »

Vaccines »

Statistics »

History »

Locations »

Contact Us »

Connect With Us:

Google +

Contact Info:

Phone: 888-447-7357


Treatments | Testimonials | Contact Us